In the first study, a multi-target kinase inhibitor, neratinib, was shown to exhibit both glycemia control and β cell protection effects in rodent diabetic models, which the authors believed is through MST1 inhibition by this drug.45 In a recent case report, the effects of MST1 inhibition were further implicated in a breast cancer patient with T2D during the treatment with neratinib, which ameliorated the hyperglycemia in the patient.46 Here, MST1 is linked to breast carcinoma.